Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
41.11
+0.20 (+0.49%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
Activist Hedge Fund Elliott Questions GSK CEO Walmsley's Leadership: Mail on Sunday
June 01, 2021
GlaxoSmithKline Plc (NYSE: GSK) appeared to dodge a potential shakeup last week when Elliott Management said it would not push the sale of its vaccines and...
Via
Benzinga
A Look Into GlaxoSmithKline's Price Over Earnings
June 01, 2021
Right now, GlaxoSmithKline Inc. (NYSE:GSK) share price is at $38.53, after a 0.62% drop. Over the past month, the stock spiked by 2.75%, but over the past year, it...
Via
Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
June 01, 2021
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT...
Via
Benzinga
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
June 01, 2021
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data....
Via
Benzinga
Exposures
COVID-19
2 Deeply Discounted Dividend Stocks to Buy and Hold Right Now
May 30, 2021
These pharmaceutical companies might make great long-term additions to your portfolio.
Via
The Motley Fool
New New Deal Worries
May 27, 2021
Nio is up 1.4% today on another round of Meme buying.
Via
Talk Markets
Activist Hedge Fund Elliott Management Backs Away from Forced GlaxoSmithKline's Vaccines, Pharma Business Sale: The Times
May 27, 2021
The Times of London reports that activist investor Paul Singer's hedge fund Elliott Management will not push the sale of GlaxoSmithKline Plc’s (NYSE...
Via
Benzinga
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
May 27, 2021
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday.
Via
Investor's Business Daily
Exposures
COVID-19
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
May 27, 2021
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021.
Via
Talk Markets
Exposures
COVID-19
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
May 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...
Via
Benzinga
Exposures
COVID-19
Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug
May 27, 2021
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ...
Via
Benzinga
Exposures
COVID-19
Product Safety
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
May 27, 2021
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope...
Via
Benzinga
Exposures
COVID-19
Market Briefing For Thursday, May 27
May 27, 2021
Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability.
Via
Talk Markets
Good Times For Gold
May 26, 2021
Gold is rising some more, in part as an alternative to crypto.
Via
Talk Markets
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
May 26, 2021
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic...
Via
Benzinga
Exposures
COVID-19
Product Safety
GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion
May 21, 2021
The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir...
Via
Benzinga
Exposures
COVID-19
Better Mood Day
May 20, 2021
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion.
Via
Talk Markets
GSK Exits Respiratory Partner Innoviva In $392M Deal
May 20, 2021
GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392...
Via
Benzinga
Cramer Shares His Thoughts On Marvell, MicroVision, More
May 20, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said Cerence Inc (NASDAQ: CRNC) is just one more software company. He doesn't want to play. Cramer wants great...
Via
Benzinga
Better Buy for 2021: GlaxoSmithKline or Sanofi?
May 20, 2021
These are two cheap stocks in an overvalued market.
Via
The Motley Fool
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
May 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
May Or May Not Happen
May 18, 2021
Another day, another drop.
Via
Talk Markets
GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response
May 18, 2021
Interim Phase 2 trial results of GlaxoSmithKline plc (NYSE: GSK) and its collaborating partner Medicago Inc’s COVID-19 vaccine candidate showed...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
May 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
COVID-19
Another Tough Day For Markets
May 17, 2021
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.”
Via
Talk Markets
Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study
May 17, 2021
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of...
Via
Benzinga
Exposures
COVID-19
73 Firms Going Ex-Dividend Next Week, Including Target, Hershey And GlaxoSmithKline
May 16, 2021
Several well known large cap stocks go ex-dividend next week including the following: Con Ed, Aflac, Target, Chevron, Eversource Energy, Magna International, Hershey Company, Walgreens Boots Alliance,...
Via
Talk Markets
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
May 13, 2021
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-...
Via
Benzinga
Exposures
COVID-19
A Down Day
May 12, 2021
The tech wreck continues because inflation will hurt the costly stock sector more than others.
Via
Talk Markets
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
May 12, 2021
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.